Cutera, Inc. (NASDAQ:CUTR) Given Consensus Recommendation of “Buy” by Analysts

Cutera, Inc. (NASDAQ:CUTRGet Rating) has received a consensus rating of “Buy” from the eight research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $71.33.

Several analysts have issued reports on CUTR shares. StockNews.com lowered Cutera from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th. Stephens boosted their target price on Cutera from $68.00 to $78.00 in a research report on Monday, May 9th. Maxim Group upped their target price on shares of Cutera from $60.00 to $80.00 in a research report on Thursday, May 5th. Stifel Nicolaus increased their price target on shares of Cutera from $60.00 to $70.00 in a research report on Monday, March 28th. Finally, Zacks Investment Research raised Cutera from a “hold” rating to a “buy” rating and set a $75.00 target price for the company in a research note on Wednesday, March 30th.

In other news, CEO David H. Mowry bought 996 shares of the firm’s stock in a transaction that occurred on Friday, May 13th. The shares were bought at an average cost of $50.12 per share, for a total transaction of $49,919.52. Following the completion of the transaction, the chief executive officer now owns 131,779 shares of the company’s stock, valued at $6,604,763.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David H. Mowry acquired 2,453 shares of Cutera stock in a transaction on Friday, March 4th. The shares were bought at an average cost of $40.81 per share, for a total transaction of $100,106.93. The disclosure for this purchase can be found here. Insiders own 2.10% of the company’s stock.

Several hedge funds have recently modified their holdings of CUTR. RTW Investments LP grew its position in shares of Cutera by 74.5% in the third quarter. RTW Investments LP now owns 1,257,862 shares of the medical device company’s stock valued at $58,616,000 after purchasing an additional 537,045 shares during the period. Millennium Management LLC raised its stake in shares of Cutera by 711.5% in the 3rd quarter. Millennium Management LLC now owns 425,230 shares of the medical device company’s stock valued at $19,816,000 after acquiring an additional 372,828 shares during the period. Emerald Advisers LLC purchased a new stake in shares of Cutera in the 1st quarter valued at approximately $19,253,000. Emerald Mutual Fund Advisers Trust purchased a new stake in Cutera during the 1st quarter worth approximately $15,956,000. Finally, BlackRock Inc. increased its stake in Cutera by 6.0% during the 4th quarter. BlackRock Inc. now owns 2,635,306 shares of the medical device company’s stock worth $108,891,000 after buying an additional 148,427 shares during the period.

Shares of NASDAQ CUTR opened at $53.53 on Friday. The company has a debt-to-equity ratio of 3.12, a current ratio of 3.20 and a quick ratio of 2.50. The company has a 50 day simple moving average of $58.24 and a 200 day simple moving average of $45.32. Cutera has a 1 year low of $31.62 and a 1 year high of $74.38. The firm has a market cap of $972.27 million, a PE ratio of -71.37 and a beta of 1.79.

Cutera (NASDAQ:CUTRGet Rating) last issued its earnings results on Tuesday, May 10th. The medical device company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.75). The firm had revenue of $58.01 million for the quarter, compared to analyst estimates of $57.26 million. Cutera had a negative return on equity of 24.42% and a negative net margin of 5.31%. Cutera’s revenue for the quarter was up 16.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.02) earnings per share. As a group, research analysts anticipate that Cutera will post 0.19 earnings per share for the current fiscal year.

Cutera Company Profile (Get Rating)

Cutera, Inc, a medical device company, researches, develops, manufactures, markets, and services laser and energy-based aesthetics systems for practitioners worldwide. The company offers Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; excel V+, a vascular and benign pigmented lesion treatment platform; truSculpt iD, for the non-surgical body sculpting market; and Secret RF, a fractional RF microneedling system for tissue coagulation and hemostasis.

Further Reading

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.